SMS Pharmaceuticals Ltd (SMSPHARMA) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- SMS Pharmaceuticals reported a strong FY25, marked by 39% PAT growth driven by volume growth, cost efficiencies, and a focused execution strategy.
- The company achieved key milestones, including launching Asia's largest dedicated and automated ibuprofen production block and investing INR 150 crores in backward integration projects.
- Successful EUGMP and US FDA audits underscore SMS Pharmaceuticals' commitment to a strong compliance culture.
- The company added new products, achieving leadership positions in several, and maintained a diversified product mix, contributing to gross margin resilience.
- For Q4 FY25, revenue grew by 43% to INR 248 crores, driven by strong demand recovery and execution.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.